|
1 Ringle I, Horwitz SB. Studies with RP56976 (taxotere): asemisy nthetic analogue of taxol. J Natl Cancer Inst, 1991,83: 288
|
|
2 Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into micro tubules induced by Taxo l and Taxotere: Reversibility,ligand stoichiometry, and competition. Biochemistry, 1993,32: 2747
|
|
3 Hennequin C, Giocanti N, Favaudon V. S -phase specificity of cell killing by docetaxel (Tax otere)in sy nchronised HeLacells. Br J Cancer, 1995, 71: 1194
|
|
4 Braakhuis BJM, Hill BT, Dietel M, et al.In vitro antiproliferative activity o f docetaxel (Taxo tere ),paclitaxel(Taxol)and cisplatin against human tumour and normal bo nemarrow cells. AnticancerRes, 19 94, 14 : 20 5
|
|
5 Zoil W, Flamigi A, Frassineti GL, et al. In vitro activity of tax ol and taxotere in comparison with doxorubicin and cisplatin on pr imary cell cultures of human breast cancers. Breast Cancer Res Treat, 1995, 34: 63
|
|
6 Vog el M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) againstfreshly explanted clonogenic human tumour cells:compar ison with tax ol and conventional antineoplastic agents. Eur J Cancer A, 1993, 29A (14): 2009
|
|
7 Chou T-C, Otter GM, Siro tnak FM. Schedule -dependent synergism of taxol or taxo tere with edatrexate againsthuman breast cancer cells in vitro.Cancer Chemother Pharmaco l, 1996, 37: 222
|
|
8 Burkhart CA, Berman JW, Swindell CS, et al. Relatio nship between the structure of tax ol and o ther taxanes on induction of tumo r necrosis facto r -αgene expression andcy totoxicity. Cancer Res, 1994, 54: 5779
|
|
9 Tag uchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP56976(docetax el)a new anticancer drug [ in Japanese].Gan to Kag aku Ry oho, 1994, 21: 1997
|
|
10 Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: aphas e Ⅱ trial of the Clinical Screening CooperativeGroup of the European Organization for Research and Treatment of Cancer.J Clin oncol, 1995, 13: 314
|
|
11 Dieras V, Chevallier B, Kerbrat P, e t al. A multicentre phase Ⅱ study of docetaxel 75 mg/ m2 as first -line chemotherapy fo r pa tients w ith adv anced breast cancer:repo rt of the Clinical Screening Group of the EORTC. Br JCancer, 1996, 74: 650
|
|
12 Ravdin PM, Bur r is Ⅲ HA, Cook G, e t al. Phase Ⅱ trial of docetaxel in advanced anthracycline -resistant or anthracenedione -resistant breast cancer.J Clin Oncol,1995, 13: 2879
|
|
13 Valero V, Holmes FA,Walters RS, e t al. Phase Ⅱ trial of docetaxel: a new, hig hly effective antineoplastic agent inthe management of patients with anthracy clin -resistant metastatic breast cancer. J Clin Oncol, 1995, 13: 2886
|
|
14 Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase Ⅱ study of the efficacy and safety of docetaxel as first -line treatment of adv anced breast cancer: Repo rt of the Clinical Screening Group of the EORTC. Ann Oncol,1996, 7: 16515 Hudis CA, Seidman AD, Crow n JPA, et al. Phase Ⅱ and pharmacologic study of docetaxel as initial chemotherapyfor metastatic breast cancer. J Clin Oncol, 1996, 14: 58
|
|
16 Trudeau ME, Eisenhauer EA, Hig gins BP, et al. Docetax el in patients with metastatic breast cancer: a phase Ⅱ study of the National Cancer Institute of Canada -Clinical Trials Group. J Clin Oncol, 1996, 14: 422
|
|
17 Ten Bokkel Huinink WW, Prove AM, Piccar t M, et al. A phase Ⅱ trial with docetaxel (Taxotere)in second line treatment with chemotherapy fo r advanced breast cancer: a study o f the EORTC Early Clinical Trials Group. Ann Oncol, 1994, 5: 527
|
|
18 Burris Ⅲ HA, Fields S, Peacock N. Docetaxel (Taxo tere)in combination: a step forw ard Semin Oncol, 1995, 95(22)Suppl. 6: 35
|
下载:
